Lallemand Health Solutions

With 90 years of know-how, we are a global leader in the probiotic industry, specializing in the development, production, and marketing of bacteria- and yeast-based probiotic supplements for human health, nutricosmetics and food applications. Our production facilities meet the highest quality standards, including Good Manufacturing Practices, and we maintain a robust research program through the Rosell Institute for Microbiome and Probiotics. We offer our partners clinically documented probiotic strains for a wide range of health applications, including gut health, immune support, mental well-being, women’s health, skin and oral health, sports, metabolic health, healthy aging, and infant health

Visit website

Profile

2026 Highlights

Example Image

Probiotics for Women’s Health: Targeted Solutions Across Life Stages

Women’s health remains a high growth, innovation-driven category, with increasing demand for evidence-based, life-stage-specific solutions. Lallemand Health Solutions has strengthened its women’s health portfolio, building on clinically documented probiotic strains addressing pregnancy, intimate health, digestive comfort during menstruation, and beyond.

  • Prenatis, evaluated in a large clinical trial involving 180 pregnant women, was shown to help reduce diagnosed maternal infections and to support the early establishment of a healthy infant gut microbiome, including in C-section-delivered newborns.
  • Lacidofil has demonstrated benefits in supporting microbial balance around C-section delivery, particularly when taken proactively, helping mitigate antibiotic-associated disruptions.
  • For intimate health, L. plantarum Rosella, one of the most extensively studied strains in this area, supported by six clinical studies involving over 800 women, has shown its ability to support vaginal microbiota balance for recurrent vulvovaginal candidiasis (rVVC) following oral administration
  • Beyond intimate health, B. bifidum Rosell-71 has demonstrated benefits for digestive comfort during menstruation, notably by reducing bloating across menstrual cycles.

Together, this body of clinical evidence illustrates the central role of microbiome-targeted probiotics in supporting women’s health across key life stages and responding to unmet needs in a fast-evolving category.

Example Image    

Mental Health: New Clinical Data on Cognitive Capacities

Lallemand Health Solutions has unveiled a new cognitive health offer supported by a recent clinical study conducted in action video gamers taking Cerebiome. Preliminary results demonstrated measurable improvements in cognitive abilities, including attention-related measurements:

 

  • Decrease in reaction time
  • Improvement in processing speed

These findings open new perspectives for cognitive capacities, expanding the company’s science-driven mental health portfolio.

Example Image

Healthy Ageing: Introducing Cerenity

Healthy aging represents another major strategic focus for 2026. Lallemand Health Solutions has launched Cerenity, a flagship probiotic solution designed to support mobility, strength, and quality of life through modulation of the gut–muscle axis. “Cerenity reflects our commitment to supporting healthy ageing from within, through clinically documented microbiome solutions,” says Camille Binachon, Marketing Group Manager, Healthy Ageing.

In a recent clinical study, Cerenity demonstrated beneficial effects on physical performance and quality of life in ageing populations. In addition, the healthy ageing portfolio continues to expand with solutions targeting cardiovascular and cognitive health, providing comprehensive support for ageing well.

Example Image

Award-Winning Postbiotic Immuse for Immune Health

Last year, Lallemand Health Solutions announced a strategic partnership with Kirin Holdings Company, Limited to expand global visibility of Immuse, the most documented postbiotics for immune support. “Immuse addresses growing demand for reliable, science-backed immune solutions applicable to daily health, sport, and skin health,” says Romane Maillet, Marketing Group Manager, Postbiotics.

Research and Development

Our research, led by the Rosell Institute for Microbiome and Probiotics, supports a diverse portfolio of probiotic strains targeting many health applications. Our team is at the forefront of innovation, with over 430 publications, more than 160 completed clinical trials, 100+ in vitro and 80+ in vivo studies, and the management of 25+ ongoing clinical trials across four continents.

Contact us: healthsolutions@lallemand.com
Visit our website for more information

Follow us on LinkedIn

Related Content